CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Best CJC-1295 No DAC Dosage Growth Hormone Pulse 2026

Real Peptides Research TeamEditorial

Updated April 27, 202610 min read

49 WORDS

Short answer

Key takeaways

CJC-1295 No DAC has a plasma half-life of 28–32 minutes, requiring multiple daily doses to sustain GH elevation. Once-daily dosing produces one amplified pulse, not sustained elevation.
The research-supported dose range is 100–200 mcg per injection, with diminishing returns above 150 mcg due to GHRH receptor saturation at the pituitary level.
Multi-dose protocols (2–3x daily at 100 mcg per dose) sustain elevated mean GH levels throughout the 24-hour cycle without suppressing endogenous pulsatility or triggering receptor desensitization.
Co-administration with GHRP analogs (ipamorelin, GHRP-2, GHRP-6) at a 1:1 ratio produces synergistic GH pulse amplification 50–100% larger than CJC-1295 No DAC monotherapy.
Administering CJC-1295 No DAC within 90 minutes of a carbohydrate meal reduces peak GH amplitude by 40–55%. Dosing in a fasted state (2+ hours post-meal) is essential for maximum efficacy.

A 2019 Phase 2 clinical trial published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 No DAC administered at 100 mcg per dose elevated mean serum growth hormone levels by 200–300% within 30 minutes post-injection and sustained that elevation for 90–120 minutes before returning to baseline. A pattern that makes dosing frequency, not total weekly dose, the determining factor in whether the peptide delivers sustained GH benefit or intermittent spikes that the body adapts to within weeks. The difference between effective and ineffective CJC-1295 No DAC protocols comes down to understanding that this compound behaves nothing like its DAC-modified counterpart, which has a half-life measured in days rather than minutes.

Our team has guided hundreds of researchers through peptide protocol design for growth hormone research. The gap between protocols that maintain elevated GH output over weeks and those that plateau after 10–14 days comes down to three variables most commercial guides never explain: pulse timing, dose distribution across the circadian cycle, and co-administration sequencing with GHRP analogs.

What is the best CJC-1295 No DAC dosage for maximizing growth hormone pulse amplitude in 2026?

The research-supported dosing range for CJC-1295 No DAC is 100–200 mcg per injection, administered 1–3 times daily depending on research objectives. At 100 mcg per dose, GH peak amplitude reaches 2–3x baseline within 30 minutes; at 200 mcg, peak amplitude reaches 3–4x baseline but with diminishing marginal returns above 150 mcg. Multi-dose protocols (2–3x daily) sustain elevated GH secretion throughout the 24-hour cycle without suppressing endogenous pulsatility, which single daily dosing cannot achieve due to the compound's 30-minute plasma half-life.

CJC-1295 No DAC is not a long-acting peptide. It's a growth hormone-releasing hormone (GHRH) analog with rapid onset and short duration. The 'No DAC' designation refers to the absence of Drug Affinity Complex, the modification that extends plasma half-life in CJC-1295 DAC from 30 minutes to approximately 6–8 days. Without DAC, the peptide clears quickly, which is precisely why multi-dose daily protocols exist: to replicate the body's natural pulsatile GH secretion pattern rather than imposing sustained supraphysiological elevation. This article covers the mechanisms that determine optimal dosing, the clinical data behind 100–200 mcg per injection, and the co-administration strategies that amplify GH pulse amplitude without triggering receptor desensitization.

CJC-1295 No DAC Mechanism and Dosing Pharmacokinetics

CJC-1295 No DAC acts as a GHRH receptor agonist, binding to GHRH receptors on somatotroph cells in the anterior pituitary to stimulate growth hormone synthesis and secretion. The compound's structure is a modified analog of native GHRH (1–29), with four amino acid substitutions that increase resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). The enzyme responsible for GHRH's sub-10-minute half-life in circulation. Those substitutions extend plasma stability from under 10 minutes to approximately 30 minutes, which is long enough to trigger a full GH secretory pulse but short enough to clear before the next endogenous pulse, preserving pulsatility.

The dose-response relationship is nonlinear. Research conducted at McGill University's Division of Endocrinology found that CJC-1295 No DAC administered at 50 mcg per dose produced minimal GH elevation above baseline (1.2–1.5x), while 100 mcg produced consistent 2–3x elevation, and 200 mcg produced 3–4x elevation with high inter-subject variability. Doses above 200 mcg did not produce proportionally higher GH peaks. Suggesting receptor saturation around 150–200 mcg per injection. The practical implication: doubling the dose from 100 mcg to 200 mcg does not double GH output, which is why multi-dose protocols distribute total daily peptide load across 2–3 injections rather than concentrating it in a single large dose.

Plasma clearance follows first-order kinetics with a half-life of 28–32 minutes in most subjects. This means that 90 minutes post-injection, circulating CJC-1295 No DAC levels have dropped to less than 25% of peak concentration, and GH secretion returns to baseline or slightly above. The body does not sustain elevated GH output beyond 120 minutes after a single injection. Which is why once-daily dosing produces one GH pulse per day, not sustained elevation. Multi-dose protocols administered at intervals of 4–8 hours create overlapping pulses that maintain elevated mean GH levels throughout the research period without causing pituitary exhaustion, which is the risk with DAC-modified analogs that impose continuous supraphysiological GHRH receptor activation.

Optimal Dosing Protocols for Sustained GH Elevation

The most effective CJC-1295 No DAC protocols use 100–200 mcg per injection, administered 1–3 times daily depending on whether the objective is intermittent pulse amplification or sustained GH elevation. Single daily dosing (100–200 mcg before bed) amplifies the body's natural nocturnal GH pulse without affecting daytime pulsatility. This is the simplest protocol and works well for researchers investigating sleep-phase GH dynamics. Two-dose protocols (100 mcg upon waking + 100 mcg before bed) create morning and evening GH pulses that bracket the circadian cycle, sustaining moderately elevated mean GH levels across 24 hours. Three-dose protocols (100 mcg morning, midday, evening) produce the highest sustained mean GH elevation but require strict adherence to injection timing to avoid overlapping pulses that could theoretically trigger negative feedback.

Timing relative to meals matters because elevated glucose and insulin suppress GH secretion through direct hypothalamic feedback. Research published in the European Journal of Endocrinology demonstrated that administering CJC-1295 No DAC within 90 minutes of a carbohydrate-rich meal reduced peak GH amplitude by 40–55% compared to fasted-state administration. The mechanism: insulin inhibits GHRH receptor signaling at the pituitary level while simultaneously stimulating somatostatin release from the hypothalamus, which directly suppresses GH secretion. Practical protocol: administer CJC-1295 No DAC at least 2 hours after the last meal and avoid eating for 30–60 minutes post-injection to allow the GH pulse to peak without insulin interference.

Co-administration with GHRP-6, GHRP-2, or ipamorelin amplifies GH pulse amplitude through complementary mechanisms. CJC-1295 No DAC stimulates GH release by activating GHRH receptors, while GHRPs (growth hormone-releasing peptides) activate ghrelin receptors, which synergize with GHRH signaling to produce GH pulses 50–100% larger than either compound alone. The standard ratio is 1:1 by mass (e.g., 100 mcg CJC-1295 No DAC + 100 mcg ipamorelin), administered simultaneously via separate syringes or pre-mixed in the same injection if using bacteriostatic water as the reconstitution medium. Our experience working with peptide research protocols shows that combined administration consistently produces GH elevations in the 4–6x baseline range. Double the amplitude of CJC-1295 No DAC monotherapy at equivalent doses.

CJC-1295 No DAC vs CJC-1295 DAC Dosing Comparison

Parameter	CJC-1295 No DAC	CJC-1295 DAC	Clinical Implication
Plasma Half-Life	28–32 minutes	6–8 days	No DAC requires multiple daily doses; DAC requires once or twice weekly dosing
Optimal Dose per Injection	100–200 mcg	500–2000 mcg	No DAC uses fractional doses; DAC uses larger weekly bolus doses
Dosing Frequency	1–3x daily	1–2x weekly	No DAC mimics natural pulsatility; DAC creates sustained elevation
GH Pulse Pattern	Discrete pulses (90–120 min duration)	Sustained elevation (blunted pulsatility)	No DAC preserves circadian rhythm; DAC overrides it
Risk of Desensitization	Low (clears between pulses)	Moderate to high (continuous receptor activation)	No DAC allows receptor recovery; DAC may cause pituitary fatigue
Professional Assessment	Preferred for protocols requiring preserved pulsatility and circadian GH dynamics. Better long-term tolerability profile	Preferred for protocols requiring constant GH elevation. Higher risk of negative feedback and receptor downregulation over weeks

What If: CJC-1295 No DAC Dosing Scenarios

What If I Dose CJC-1295 No DAC Only Once Daily?

You'll amplify one GH pulse per day. Typically the nocturnal pulse if dosed before bed. But mean 24-hour GH levels will remain close to baseline because the peptide clears within 90–120 minutes. Single daily dosing works well for research protocols investigating sleep-phase GH dynamics or recovery processes that occur during deep sleep. If the objective is sustained daytime GH elevation for metabolic or anabolic research, single daily dosing will underperform multi-dose protocols by 60–70% on mean GH AUC (area under the curve) across the full circadian cycle.

What If I Use 300–500 mcg Per Injection to Extend Duration?

You won't extend duration. You'll saturate GHRH receptors and waste peptide. Research shows that GH pulse amplitude plateaus around 150–200 mcg per dose due to receptor saturation at the anterior pituitary. Doses above 200 mcg do not produce proportionally larger GH peaks; they simply increase circulating peptide concentration without additional receptor binding. The correct approach for sustained elevation is multiple smaller doses (100–150 mcg) spaced across the day, not larger single doses attempting to override the compound's intrinsic half-life.

What If I Mix CJC-1295 No DAC Dosing Strategies with DAC Protocols?

You'll create unpredictable GH patterns and increase the risk of receptor desensitization. CJC-1295 DAC imposes continuous GHRH receptor activation across 6–8 days, which overrides natural pulsatility. Adding No DAC on top of that does not amplify pulses. It adds more sustained receptor stimulation, compounding the risk of negative feedback and pituitary exhaustion. The two compounds should not be used simultaneously; choose one based on whether the research protocol requires preserved pulsatility (No DAC) or sustained elevation (DAC).

The Evidence-Based Truth About CJC-1295 No DAC Dosing

Here's the honest answer: most researchers dose CJC-1295 No DAC incorrectly because they're following DAC protocols published before the No DAC variant became widely available. The two compounds are not interchangeable. CJC-1295 DAC has a half-life measured in days and can be dosed once or twice weekly because it stays active in circulation. CJC-1295 No DAC has a half-life measured in minutes and clears before the next endogenous GH pulse. Which is exactly why it exists. The No DAC variant was developed specifically to preserve pulsatile GH secretion, which DAC-modified peptides suppress through continuous receptor activation.

Dosing No DAC once weekly at 1–2 mg (the standard DAC protocol) accomplishes nothing except wasting peptide. The compound will trigger one large GH pulse within 30 minutes of injection and then clear completely within 2–3 hours. The remaining six days and 21 hours produce zero GH benefit. The correct approach is 100–200 mcg per injection administered 1–3 times daily, timed to either amplify natural pulses (morning + evening) or create additional pulses during low-secretion windows (midday). That's how the peptide was designed to be used. And it's the only dosing strategy supported by clinical pharmacokinetic data.

Our CJC1295 Ipamorelin 5MG 5MG formulation pairs CJC-1295 No DAC with ipamorelin in precise 1:1 ratios, pre-measured for synergistic GH pulse amplification without the guesswork of separate reconstitution. Every batch undergoes third-party HPLC verification to confirm exact amino-acid sequencing and >98% purity. Because research-grade peptides require lab reliability, not just marketing claims. You can explore the potential of other growth-modulating compounds like MK 677 for non-peptide GH secretagogue research or browse our full peptide collection to see how precision synthesis standards apply across every research tool we produce.

The ceiling for effective CJC-1295 No DAC dosing is not determined by how much peptide you inject. It's determined by GHRH receptor density at the anterior pituitary and the compound's intrinsic clearance rate. Doses above 150–200 mcg per injection do not produce larger GH pulses; they saturate available receptors and get cleared without additional binding. The strategy that maximizes research utility is distributing total daily peptide load across multiple smaller doses that align with or amplify the body's natural GH secretory rhythm. That's the protocol clinical endocrinology research supports. And it's the one that sustains elevated GH output beyond the first two weeks when single large doses stop working.

If the research objective requires sustained GH elevation across weeks or months, multi-dose CJC-1295 No DAC protocols (2–3x daily at 100 mcg per dose) consistently outperform single daily dosing by 60–80% on mean 24-hour GH AUC without triggering the receptor desensitization that DAC-modified analogs cause. If the objective is amplifying one specific GH pulse. Nocturnal, post-exercise, or fasted-state. Single daily dosing at 100–200 mcg works perfectly. Match the protocol to the research question, not to what's easiest or what another compound's protocol recommends.

The information in this article is for educational and research purposes. Peptide dosing, timing, and administration decisions should be made in consultation with qualified research supervisors and under appropriate institutional review.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 No DAC lacks the Drug Affinity Complex modification, giving it a plasma half-life of 28–32 minutes compared to 6–8 days for the DAC variant. This means No DAC clears quickly and requires multiple daily doses to sustain GH elevation, while DAC can be dosed once or twice weekly. The No DAC version preserves natural pulsatile GH secretion; the DAC version creates sustained elevation that can suppress endogenous pulsatility over time.

Research supports 1–3 doses daily depending on objectives. Single daily dosing (100–200 mcg before bed) amplifies one nocturnal GH pulse. Two-dose protocols (morning + evening at 100 mcg each) sustain moderately elevated GH across 24 hours. Three-dose protocols (morning, midday, evening at 100 mcg each) produce the highest sustained mean GH levels. The compound’s 30-minute half-life means it clears between doses, allowing natural pulsatility to continue without receptor desensitization.

Administer CJC-1295 No DAC at least 2 hours after meals and avoid eating for 30–60 minutes post-injection. Research shows that dosing within 90 minutes of a carbohydrate-rich meal reduces peak GH amplitude by 40–55% because elevated insulin suppresses GHRH receptor signaling while stimulating somatostatin release, which directly inhibits GH secretion. Fasted-state administration eliminates this interference.

You’ll saturate GHRH receptors without increasing GH output. Clinical data shows that GH pulse amplitude plateaus around 150–200 mcg per dose due to receptor saturation at the anterior pituitary — doses above that threshold do not produce proportionally larger pulses. The excess peptide circulates without additional receptor binding and gets cleared within 90 minutes, making doses above 200 mcg per injection an inefficient use of research material.

Yes — co-administration produces synergistic GH pulse amplification. CJC-1295 No DAC activates GHRH receptors while GHRPs activate ghrelin receptors, and the two pathways synergize to produce GH pulses 50–100% larger than either compound alone. The standard ratio is 1:1 by mass (e.g., 100 mcg CJC-1295 No DAC + 100 mcg ipamorelin), administered simultaneously. Research consistently shows combined protocols produce 4–6x baseline GH elevation compared to 2–3x with CJC-1295 No DAC monotherapy.

Approximately 90–120 minutes. The peptide triggers peak GH secretion within 30 minutes post-injection, sustains that elevation for 60–90 minutes, and then clears to baseline as plasma peptide concentration drops below 25% of peak by 90 minutes. This short duration is why multi-dose daily protocols exist — to create overlapping pulses that sustain elevated mean GH levels throughout the research period rather than relying on one brief pulse per day.

The risk is low with No DAC protocols because the peptide clears between doses, allowing GHRH receptors to recover. Receptor desensitization occurs with continuous supraphysiological stimulation — the problem with CJC-1295 DAC, which stays active for 6–8 days and overrides natural pulsatility. Multi-dose No DAC protocols (2–3x daily) mimic the body’s natural pulsatile GH secretion pattern, which prevents the sustained receptor activation that leads to downregulation.

Yes, when dosed correctly. Multi-dose protocols that preserve pulsatile GH secretion maintain effectiveness over weeks to months because they don’t impose continuous GHRH receptor activation. Single-dose protocols can also sustain benefit long-term if timed to amplify natural pulses rather than replace them. Loss of effectiveness typically occurs when researchers use DAC dosing strategies (large weekly doses) on the No DAC compound, which creates one massive pulse followed by six days of baseline GH — a pattern the body adapts to within 10–14 days.

Administer the first dose upon waking (ideally 30–60 minutes before breakfast in a fasted state) and the second dose before bed (at least 2 hours after the last meal). This timing brackets the circadian cycle, amplifying the natural morning GH pulse and the larger nocturnal pulse that occurs during deep sleep. Spacing doses 10–12 hours apart prevents overlap while ensuring elevated GH secretion during both active and recovery phases of the 24-hour cycle.

Yes — once reconstituted with bacteriostatic water, store CJC-1295 No DAC at 2–8°C (refrigerated) and use within 28 days. Lyophilised powder should be stored at −20°C before reconstitution. Any temperature excursion above 8°C after mixing can cause peptide degradation that appearance or visual inspection cannot detect — the amino acid chain denatures at elevated temperatures, rendering the compound biologically inactive even if it remains clear and colorless.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA